Drug intelligence / Profile preview

Socketol

Development stage: Unknown
Lead developer: lege artis Pharma
Modality: Small Molecules
Administration: Topical

Overview

Socketol is a dental surgical preparation developed by lege artis Pharma for the management of tooth extraction sockets. It is specifically indicated for the treatment of alveolitis (dry socket) and as a prophylactic agent following tooth extraction. The formulation acts as both an analgesic and an antiseptic. It contains lidocaine hydrochloride monohydrate for local anesthesia, phenoxyethanol and thymol for antiseptic properties, and Peru balsam, which supports wound healing. The paste is applied directly into the alveolus (tooth socket) to alleviate pain and prevent or treat infection when the blood coagulum has disintegrated.

Brand names: Socketol
Other names: The dry-SOCKET-paste

Targets

SCN1A (Voltage-gated sodium channel protein type 1 subunit alpha)

Beyond the preview

Go deeper on Socketol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Socketol.

Explore the full profile